Keywords: consensus, estimates, novo, nordisk, still, too, high
Consensus estimates for Novo Nordisk still "too high," says MSDW
Article | 24 May 1999
Novo Nordisk's first-quarter 1999 results (Marketletter May 17) werebetter than analysts at Morgan Stanley Dean Witter had expected, and were boosted by ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
